ReachRxResearch
Home
Research
Sign Up
Prefibrotic bone marrow microenvironment is a hallmark of clonal hematopoiesis
Back to Research Hub
  1. Home
  2. Research Hub
  3. Prefibrotic bone marrow microenvironment…

Prefibrotic bone marrow microenvironment is a hallmark of clonal hematopoiesis

Nature Immunology·September 30Open Access
ImmunologyPractice changingBone Marrow FibrosisClonal Hematopoiesis Of Indeterminate PotentialCross-Sectional StudyHistologySingle-Cell TranscriptomicsSpatial TranscriptomicsAdult

Summary

View source

What was studied

This study examined how clonal hematopoiesis of indeterminate potential (CHIP) remodels the bone marrow (BM) microenvironment, using single-cell transcriptomics, histology, and spatial transcriptomics of freshly isolated BM samples from CHIP patients.

Key findings

CHIP is marked by fibro-inflammatory BM remodeling: fibroblasts expanded and adopted cancer-associated fibroblast-like states, mesenchymal and vascular cells upregulated collagen and extracellular matrix pathways, and spatial transcriptomics pinpointed discrete fiber-enriched inflammatory hubs enriched for TGF-β and TNF signaling, populated by active and CXCL12+ fibroblasts, macrophages, and lymphoid cells.

Study limitations

The study is cross-sectional and observational, so it cannot establish causality or the temporal sequence of stromal changes relative to clonal expansion; sample size and specific demographic details of the CHIP cohort are not reported in the abstract; generalizability across different CHIP driver mutations is unclear.

Clinical implications

Clinicians managing CHIP patients should be aware that prefibrotic stromal changes in the bone marrow may be an early, measurable sign of disease progression toward overt malignancy, potentially warranting closer surveillance for myelofibrosis or hematologic malignancy.

Caveats

  • Causality between CHIP-driven clonal expansion and fibro-inflammatory stromal remodeling cannot be established from this cross-sectional design alone
  • Findings may not apply equally across all CHIP driver mutations (e.g., DNMT3A, TET2, ASXL1), as mutation-specific effects on the BM microenvironment are not delineated in the abstract
  • The abstract does not report a specific sample size, limiting assessment of statistical power and generalizability
Show all 4
  • The paper is published September 30, 2026 — very recently; findings have not yet been externally replicated or validated in independent cohorts

Related Questions

Explore related topics

What are the clinical risk factors for progression from CHIP to myeloid malignancy?How does TGF-beta signaling drive bone marrow fibrosis in myeloproliferative neoplasms?Can bone marrow biopsy findings in CHIP predict transformation to myelofibrosis or AML?

Publication Details

Year
2026
Journal
Nature Immunology
Source
View article
Keep scrolling
More content below.
Up Next